Baidu
map

Clin Cancer Res:PD-1抗体Geptanolimab治疗罕见肺泡软组织肉瘤的活性

2020-11-07 星云 MedSci原创

肺泡软组织肉瘤(ASPS)是一种罕见的疾病,治疗方法也少。该研究评估了geptanolimab (GB226),一种完全人源化的程序性细胞死亡蛋白1抗体,用于不可切除的、复发或转移性ASPS患者的活性

肺泡软组织肉瘤(ASPS)是一种罕见的疾病,治疗方法也少。该研究评估了geptanolimab (GB226),一种完全人源化的程序性细胞死亡蛋白1抗体,用于不可切除的、复发或转移性ASPS患者的活性。

该研究是一项多中心、单臂的II期试验(Gxplore-005),在我国11个地点招募了18-75岁的、不可切除的、复发性或转移性ASPS患者,予以geptanolimab(3 mg/kg,静滴,1次/2周)治疗,直到病情进展或出现不可耐受的毒性。主要终点是客观缓解率。

2018年9月6日-2019年9月6日,共招募了37位患者接受geptanolimab治疗,其中23位(62.2%)既往接受过系统治疗。

14位(37.8%)患者获得客观缓解,6个月持续缓解率达到91.7%。中位无进展存活期为6.9个月,32位(86.5%)患者获得病程控制。

3位患者报告了3级治疗相关不良反应(TRAE),包括贫血、下垂体炎和蛋白尿(各一例[2.7%])。无4级TRAE。两位(5.4%)患者因TRAE终止治疗。CD4+T细胞的基础百分比与患者反应情况呈负相关。

综上所述,geptanolimab用于不可切除的复发性/转移性ASPS可获得具有临床意义的疗效,而且安全性可控。

原始出处:

Yuankai Shi, et al. Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study. Clin Cancer Res November 6 2020 DOI:10.1158/1078-0432.CCR-20-2819

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2065896, encodeId=60d620658968f, content=<a href='/topic/show?id=8ab48214924' target=_blank style='color:#2F92EE;'>#肺泡软组织肉瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82149, encryptionId=8ab48214924, topicName=肺泡软组织肉瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Sun Sep 12 03:21:15 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912474, encodeId=91d319124e4b5, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Sep 29 14:21:15 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420464, encodeId=d365142046404, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Mon Nov 09 09:21:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467583, encodeId=25be146e5839f, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Nov 09 09:21:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577109, encodeId=aec815e7109ad, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13914, encryptionId=a2a613914cd, topicName=PD-1抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=021d16387966, createdName=1249857fm37暂无昵称, createdTime=Mon Nov 09 09:21:15 CST 2020, time=2020-11-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2065896, encodeId=60d620658968f, content=<a href='/topic/show?id=8ab48214924' target=_blank style='color:#2F92EE;'>#肺泡软组织肉瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82149, encryptionId=8ab48214924, topicName=肺泡软组织肉瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Sun Sep 12 03:21:15 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912474, encodeId=91d319124e4b5, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Sep 29 14:21:15 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420464, encodeId=d365142046404, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Mon Nov 09 09:21:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467583, encodeId=25be146e5839f, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Nov 09 09:21:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577109, encodeId=aec815e7109ad, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13914, encryptionId=a2a613914cd, topicName=PD-1抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=021d16387966, createdName=1249857fm37暂无昵称, createdTime=Mon Nov 09 09:21:15 CST 2020, time=2020-11-09, status=1, ipAttribution=)]
    2021-09-29 snf701207
  3. [GetPortalCommentsPageByObjectIdResponse(id=2065896, encodeId=60d620658968f, content=<a href='/topic/show?id=8ab48214924' target=_blank style='color:#2F92EE;'>#肺泡软组织肉瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82149, encryptionId=8ab48214924, topicName=肺泡软组织肉瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Sun Sep 12 03:21:15 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912474, encodeId=91d319124e4b5, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Sep 29 14:21:15 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420464, encodeId=d365142046404, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Mon Nov 09 09:21:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467583, encodeId=25be146e5839f, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Nov 09 09:21:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577109, encodeId=aec815e7109ad, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13914, encryptionId=a2a613914cd, topicName=PD-1抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=021d16387966, createdName=1249857fm37暂无昵称, createdTime=Mon Nov 09 09:21:15 CST 2020, time=2020-11-09, status=1, ipAttribution=)]
    2020-11-09 qilu_qi
  4. [GetPortalCommentsPageByObjectIdResponse(id=2065896, encodeId=60d620658968f, content=<a href='/topic/show?id=8ab48214924' target=_blank style='color:#2F92EE;'>#肺泡软组织肉瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82149, encryptionId=8ab48214924, topicName=肺泡软组织肉瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Sun Sep 12 03:21:15 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912474, encodeId=91d319124e4b5, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Sep 29 14:21:15 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420464, encodeId=d365142046404, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Mon Nov 09 09:21:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467583, encodeId=25be146e5839f, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Nov 09 09:21:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577109, encodeId=aec815e7109ad, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13914, encryptionId=a2a613914cd, topicName=PD-1抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=021d16387966, createdName=1249857fm37暂无昵称, createdTime=Mon Nov 09 09:21:15 CST 2020, time=2020-11-09, status=1, ipAttribution=)]
    2020-11-09 syscxl
  5. [GetPortalCommentsPageByObjectIdResponse(id=2065896, encodeId=60d620658968f, content=<a href='/topic/show?id=8ab48214924' target=_blank style='color:#2F92EE;'>#肺泡软组织肉瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82149, encryptionId=8ab48214924, topicName=肺泡软组织肉瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Sun Sep 12 03:21:15 CST 2021, time=2021-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912474, encodeId=91d319124e4b5, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Wed Sep 29 14:21:15 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420464, encodeId=d365142046404, content=<a href='/topic/show?id=2221935219e' target=_blank style='color:#2F92EE;'>#软组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93521, encryptionId=2221935219e, topicName=软组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52913579937, createdName=qilu_qi, createdTime=Mon Nov 09 09:21:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467583, encodeId=25be146e5839f, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Nov 09 09:21:15 CST 2020, time=2020-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577109, encodeId=aec815e7109ad, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13914, encryptionId=a2a613914cd, topicName=PD-1抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=021d16387966, createdName=1249857fm37暂无昵称, createdTime=Mon Nov 09 09:21:15 CST 2020, time=2020-11-09, status=1, ipAttribution=)]

相关资讯

全球针对肝癌的PD-1抗体获FDA批准,奋起直追,国产PD-1抗体顺利进入三期临床

作为一项严重的全球性健康问题,肝癌(HCC)是癌症相关死亡率的第二大原因,肝癌(HCC)难治已是众所周知!全球每年约有782,000例新发病例,造成的死亡人数约为746,000例。而中国约占全球新发HCC病例和HCC相关死亡人数的50%。也就是说,全世界几乎一半的肝癌患者都在中国。此外,国内大部分的肝癌患者,发现就是晚期,没有了手术的机会。但就目前来看,治疗晚期肝癌的药物并不多,对于这类患者来说,

MSD的keytruda在非小细胞肺癌的另一项临床试验中大获成功

默沙东公司(MSD)的Keytruda在一线治疗中无论患者PD-L1的表达水平如何,均能显着提高肺癌患者的总生存期。这一结果显着增加了Keytruda的临床治疗范围。

EUR J CANCER:Nivolumab相关的免疫不良事件:恶心和呕吐

大红大紫的免疫治疗,包括CAR-T疗法及程序性细胞死亡蛋白1(PD-1)抗体疗法,重磅药物PD-1/PD-L1抗体已经累计被批准了11个肿瘤适应症,包括黑色素瘤、非小细胞肺癌、肾细胞癌、霍奇金淋巴瘤、头颈癌、膀胱癌、结直肠癌、胃癌、肝癌、默克尔细胞癌以及错配修复缺陷(dMMR)的实体瘤。PD-1抗体Nivolumab已经被用于转移性黑色素瘤及鳞状非小细胞肺癌的治疗。尽管,相比于具有细胞毒性的T淋巴

JCI:Dinaciclib诱导免疫原性细胞死亡并增强PD-1抗体介导的肿瘤抑制

免疫检查点(PD-1)抑制剂已经在治疗癌症的临床上中显示出了巨大的成功,然而,大多数肿瘤对PD-1抗体的单一疗法具有抗性。许多正在进行的联合治疗研究揭示出PD-1抗体与其他治疗药物的相互补充可能产生更好的效果。

JCI:IFN-γ相关mRNA数据能够预测患者对PD-1抗体的响应

JCI:IFN-γ相关mRNA数据能够预测患者对PD-1抗体的响应 Pembrolizumab已经被广泛用于晚期黑色素瘤的治疗,相比于化疗或伊匹单抗,pembrolizumab能够显著提高晚期黑色素瘤患者的总生存期。 靶向程序化死亡蛋白(PD-1)从而实现肿瘤细胞

EUR J CANCER:转移性皮肤顶浆分泌腺癌对PD-1抗体pembrolizumab的响应

皮肤顶浆分泌腺癌(Cutaneous apocrine adenocarcinoma)是一种罕见的汗腺癌,其发病部位多处于上躯干和头/颈部区域。对于该疾病,预测患者生存期的最重要的评判标准即为阳性淋巴结状态。而对于转移性皮肤顶浆分泌腺癌患者,目前尚无有效的治疗方法,因此患者5年总生存率低于10%。

Baidu
map
Baidu
map
Baidu
map